

Wednesday, 26 November 2025

13:00 – 15:00	Session I: The Bone Marrow Niche in Haemoglobinopathies Chairs: Ferroptosis and Iron Haemostasis in BM and Inflammation Is SCD a pre-cancerous condition: Clonality in SCD Ineffective erythropoiesis Recent advances in iron homeostasis Round table discussion: <i>Are the intrinsic features of these disorders making transplantation difficult?</i>	
15:00 – 15:30	Coffee Break	
15:30 – 16:00	Keynote Lecture Chair: Advances in non-cellular therapies	
16:00 – 17:30	Session II: The problem of NTDT: an orphan haemoglobinopathy Chairs: Introduction and Natural History of NTDT Mechanism of switch to transfusion dependence Modern treatment of NTDT Round table discussion: <i>Is there a role for BMT or gene therapy (non-transplanter point of view)?</i>	Nica Capellini (IT) Valeria Pinto (IT)
17:30 – 18:00	Poster Walk	

Thursday, 27 November 2025
Main Track

09:30 – 10:00	Roundtable discussion: <i>Are all approaches the same?</i>	
10:00 – 11:00	Session III (part I): Gene Editing, Gene Therapy, Gene Correction Chairs:	
10:00 – 10:20	Update on Zynteglo for TDT	
10:20 – 10:40	Update on Lytfia for SCD	
10:40 – 11:00	Update on Casgevy for TDT	
11:00 – 11:30	Coffee Break	
11:30 – 12:30	Session III (part II): Gene Editing, Gene Therapy, Gene Correction Chairs:	
11:30 – 12:00	Update on Casgevy for SCD	
12:00 – 12:30	Update on BEACON study for SCD	
12:30 – 13:15	Lunch Break	
13:15 – 14:15	Industry Symposium	
14:15 – 15:45	Session III (part III): Gene Editing, Gene Therapy, Gene Correction Chairs:	
14:15 – 14:35	Strategies for successful apheresis collection and post dosing care	
14:35 – 14:55	Optimal busulfan delivery	
14:55 – 15:15	Immune reconstitution & long-term care management	
15:15 – 15:35	Real-world experience: REGENT	
15:35 – 15:45	Round table discussion: <i>What are the priorities for a successful programme?</i>	
15:45 – 16:15	Coffee Break	
16:15 – 17:00	Industry Symposium	
17:00 – 18:00	Session IV: Alternative Donor Transplantation Chairs: Fabio Giglio (IT)	
17:00 – 17:20	PTCy RIC transplantation (for adults & children)	Adetola Kassim (US)
17:20 – 17:40	Graft manipulation for haemoglobinopathies	
17:40 – 18:00	Patient selection for curative therapies	Monica Bathia (US)

Thursday, 27 November 2025
Nurses' Track

09:30 – 11:00	Session I (part I): Pre-transplant care Chairs: Introductions Supportive care in sickle cell disease Supportive care in thalassaemia Indication and outcomes of HSCT Preparation for standard HSCT
11:00 – 11:30	Coffee Break
11:30 – 12:30	Session I (part II): Pre-transplant care Chairs: Donor selection: use of haploidentical donors in haemoglobinopathies Use of pre transplant immunosuppression (PTIS) in TDT Use of reduced toxicity regimens in patients (>16) with HLA matched siblings
12:30 – 13:15	Lunch Break
13:15 – 14:15	Industry Symposium
14:15 – 15:45	Session II: Gene Editing, Gene Therapy, Gene Correction Chairs: Gene therapy: is this the new way forward? Gene therapy preparation: how does it differ to HSCT preparation? Mobilisation and optimising stem cell collections Case study Updates from the clinical trials & future trials
15:45 – 16:15	Coffee Break
16:15 – 17:00	Industry Symposium
17:00 – 18:00	Session III: The role of MDT members and patient perspective Chairs: Role of the clinical psychologist for patients with haemoglobinopathies Role of the physiotherapist in patients with haemoglobinopathies Patient perspective (TIF)

Regensburg, Germany
26-28 November 2025

Friday, 28 November 2025

08:00 – 09:30	Haemoglobinopathies Working Party Annual Meeting Business Meeting <i>Open to all.</i>	
09:30 – 11:00	Session V: Resource Limited Setting Chairs:	
09:30 – 09:45	Challenges & priorities of allogeneic transplantation in Tanzania	Stella Malangahe (TZ)
09:45 – 10:00	Challenges & priorities of allogeneic transplantation in Nigeria	
10:00 – 10:15	Challenges & priorities of allogeneic transplantation in unequal settings	Lawrence Faulkner (IT)
10:15 – 10:30	Does gene therapy have a role in resource limited setting	
10:30 – 11:00	Roundtable discussion: <i>Is the role for curative therapies in resource limited settings?</i>	
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session VI: Alternative Donor Transplantation-Improving Outcomes Chairs: <i>Monica Bhatia (US)</i>	
11:30 – 11:50	The role of AI in transplantation	
11:50 – 12:10	Cerebrovascular disease: reversibility or stabilisation?	Francoise Bernaudin (FR)
12:10 – 12:30	Utility and outcomes of transplantation of psychometric tests	Becky Armstrong (UK)
12:30 – 12:50	Reversibility of iron damage	
12:50 – 13:00	Effect of BMT on sickle cell disease-related organ complications	Erfan Nur (NL)
13:00 – 13:30	Farewell Lunch	